CJC-1295 No DACUnderstand the science
From a growth hormone signal to an outcome in people
1 numbered sourceSource years 2024
Short chains of amino acids linked by peptide bonds can work as messages from one tissue to another. CJC-1295 No DAC generally refers to Mod GRF (1–29), a 29-residue analogue designed around the natural signal for growth hormone release. An important research question is how a hormone measurement could be connected to an outcome that matters to people with growth hormone deficiency. [1]
That connection has several steps. First comes the question of whether the precise compound activates the receptor in a controlled experiment. Then researchers can ask whether it changes blood growth hormone concentrations and, over time, changes insulin-like growth factor 1 (IGF-1). IGF-1 is one of the body's downstream responses to growth hormone. Even if those measurements move as expected, a trial designed to evaluate treatment would still need to assess outcomes in people with the condition. [1]
When the FDA evaluated growth hormone deficiency as a proposed use in 2024, it found no clinical effectiveness studies in people with that condition for the CJC-1295 forms it assessed. It also found no human studies of the specific no-DAC free base or its acetate salt. The published human studies it could identify used the DAC active molecule and focused on healthy adults. [1]
No recent primary study was identified here that closes the gap for the no-DAC form. The older regulatory briefing distinguishes the proposed indication from the evidence actually available. A clinical study would need to define who has the condition, choose a relevant comparison group and follow a suitable outcome over time. Short-term changes in a laboratory result would provide one part of that evidence. [1]
Sources
Original works cited in this article. Links open the external record in a new tab.
